CCTG has opened the anticipated international brain cancer study CCTG CE9 (LUMOS2) - joining forces with the Australian Cooperative Trials Group for Neuro-Oncology (COGNO) to make enrollment accessible to Canadian patients.
MODERN: An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer
Radiotherapy to Block (CURB2) Oligoprogression In Metastatic Non-Small-Cell Lung Cancer
Comparing Palliative Stereotactic Body Radiotherapy vs. Palliative Standard Radiotherapy in Patients with Advanced Head and Neck Cancer
LND101 for Fecal Microbiota Transplantation in Combination with Immune Checkpoint Blockade in Patients with Advanced Melanoma
The CCTG ES3 NEEDS international esophageal cancer clinical trial is now opened in Canada. The study is investigating whether delaying surgery for patients with squamous cell carcinoma of the esophagus is as good as the current treatment.
Eradicating MRD in Patients with AML prior to Stem Cell Transplant (ERASE)
VIGOR: Vorasidenib as Maintenance Treatment after First-line Chemoradiotherapy in IDH-mutant Grade 2 or 3 Astrocytoma
Botensilimab + Balstilimab or Botensilimab Alone vs Best Supportive Care as Therapy in Chemo-refractory, Advanced, Colorectal Adenocarcinoma: The BATTMAN Trial
STRIDE (durvalumab + tremelimumab) with Lenvatinib vs STRIDE Alone in Patients with Unresectable Hepatocellular Carcinoma (SLIDE-HCC)
CALMS: Combination Therapy with Luspatercept in Lower Risk MDS CTEP approval: 2024AUG27 (date of US Steering Committee Evaluation)
Lanreotide for the Prevention of Postoperative Pancreatic Fistula
The CCTG Gastro-Intestinal Disease Site Committee would like to recognize Dr Vincent Barrette and Dr Anthony Lott for their accrual contributions to the CRC10 study as new investigators.
CCTG will be holding the next CRA Lunch and Learn on Wednesday January 22nd, 2025, at 12 pm ET. Session 2 will cover the topic of CCTG Website Navigation and Communications.
MA41 trial investigating a de-Escalation of adjuvant chemotherapy in HER-2 positive, estrogen receptor-negative, node-negative, early breast cancer patients who achieved pathological complete response after neoadjuvant chemotherapy and dual HER-2 blockade (DECRESCENDO) trial has now permanently closed.
In April 2024, at the CCTG Spring Meeting of Participants, the CCTG Patient Representative Committee members participated in a facilitated session designed to identify the research topics that Committee members view as being most important to cancer patients and caregivers. The outcome of the workshop resulted in the identification by the CCTG reps of six Cancer Research Priorities.
The Canadian Cancer Trials Group would like to extend our sincere gratitude to Erwin Wanderer, Bob Taylor, and Martina Wood for their commitment and dedication to the CCTG Patient Representative Committee. Erwin, Bob and Martina have completed their term on the committee and will be moving on from their invaluable role at CCTG at the end of 2024.
